An Ebola vaccine candidate based on controlled expression of antigen through the recombinant adenovirus system

Background: The 2014 outbreak of Ebola haemorrhagic fever (EHF) has claimed > 11,000 lives. No vaccines or antivirals are available for EHF, but are currently the subject of intense investigations. Several vaccines targeting the Ebola virus glycoprotein (GP) are currently under different phases of clinical testing, where GP is delivered through chimpanzee adenovirus (Ad) 3 (GlaxoSmithKline), vesicular stomatitis virus (Merck), human Ad26 and35 (Johnson & Johnson) or human Ad5 (Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology).

Source: International Journal of Infectious Diseases - March 29, 2016 Category: Infectious Diseases Authors: D. Kumar, S. Gauthami, U. Madala, P. Panduranga Rao, K. Ella, N.R. Hegde Tags: Type: Poster Presentation Source Type: research